BioCentury
ARTICLE | Financial News

Tmunity raises $100M series A

January 26, 2018 5:09 PM UTC

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised $100 million in a series A round Tuesday from new investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc. (NASDAQ:GILD) and Be The Match BioTherapies. Existing investors Penn Medicine and Lilly Asia Ventures, which both funded the company's $10 million seed round, also participated.

Tmunity was founded by Carl June and other faculty and researchers at the University of Pennsylvania. It has an exclusive license to platforms from the university to develop and commercialize engineered T cell immunotherapies for cancer, infectious diseases and autoimmune diseases, including T cell receptors (TCRs), regulatory T cells and chimeric antigen receptor (CAR) T cells...